Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Gynecologic 2Gastrointestinal 2Dermatologic 2Plasma cell 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Melanoma 34Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Neoplasms 3Brain Neoplasms 3Skin Neoplasms 2Neoplasms by Site 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Noonan Syndrome 1Neoplasms, Squamous Cell 1Neoplasms by Histologic Type 1Multiple Myeloma 1Lung Neoplasms 1Lung Diseases 1Laryngeal Neoplasms 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Erdheim-Chester Disease 1

Interventions

cobimetinib 2spartalizumab 1pembrolizumab 1osimertinib 1glutathione pegylated liposomal doxorubicin 1entrectinib 1atezolizumab 1alectinib 1Vemurafenib 1Trastuzumab 1Taxes 1Radiosurgery 1Pemetrexed 1Paclitaxel 1Nivolumab 1HuMax-IL8 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Site × cobimetinib × Dermatologic × Clear all
NCT05768178 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Revolution Medicines, Inc.

Phase 1/2 Completed
113 enrolled 22 charts
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡